<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">RISEDRONATE SODIUM</span><br/>(ri-se-dron'ate)<br/><span class="topboxtradename">Actonel<br/></span><b>Classifications:</b> <span class="classification">bisphosphonate</span>; <span class="classification">regulator, bone metabolism</span><br/><b>Prototype: </b>Etidronate Disodium<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 30 mg, 35 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Diphosphate preparation with primary action on bone. Mechanism of action not fully understood. Lowers serum alkaline phosphatase,
         presumably by decreasing release of phosphate from bone and increasing excretion of parathyroid hormone.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Indicated by decreased bone and joint pain and improved bone density. Slows rate of bone resorption and new bone formation
         in pagetic bone lesions and in normal remodeling process. One thousand times more potent than etidronate.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Paget's disease, prevention and treatment of postmenopausal osteoporosis and steroid-induced osteoporosis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to risedronate or other bisphosphonates; hypocalcemia, vitamin D deficiency; lactation; severe renal impairment
         (creatinine clearance 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment; CHF; hyperphosphatemia; hepatic disease; fever related to infection or other causes. Safety and efficacy
         in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Paget's Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 30 mg q.d. at least 30 min before the first food or drink of the day times 2 mo, may repeat after 2 mo rest if necessary<br/><br/><span class="indicationtitle">Prevention &amp; Treatment of Osteoporosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 5 mg q.d. 30 min before first food or drink or one dose of 35 mg weekly<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give on an empty stomach (before first food or drink of the day) with at least 68 oz plain water.</li>
<li> 				Note: Patient should be upright. Maintain upright position and empty stomach for at least 30 min after administration. 			</li>
<li>Space calcium supplements and antacids as far as possible from risedronate.</li>
<li>Store at 15°30° C (59°86° F) in a tightly closed container and protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Flu-like syndrome, asthenia, arthralgia, bone pain, leg cramps, myasthenia. <span class="typehead">CNS:</span> Headache, dizziness. <span class="typehead">CV:</span> Chest pain, peripheral edema. <span class="typehead">GI:</span> <span class="speceff-common">Diarrhea,</span> abdominal pain, nausea, constipation, belching, colitis. <span class="typehead">Respiratory:</span> Bronchitis, sinusitis. <span class="typehead">Skin:</span> Rash. <span class="typehead">Special Senses:</span> Amblyopia, tinnitus, dry eyes. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>May interfere with the use of bone-imaging agents.</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Calcium,</b> <span class="classification">antacids</span> significantly decrease absorption. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Minimally absorbed from GI tract, bioavailability 0.63%. <span class="typehead">Peak:</span> 1 h. <span class="typehead">Distribution:</span> Approximately 60% of dose is distributed to bone. <span class="typehead">Metabolism:</span> Not metabolized. <span class="typehead">Elimination:</span> Excreted in urine; unabsorbed drug excreted in feces. <span class="typehead">Half-Life:</span> 220 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Baseline and periodic serum calcium, phosphorus, and alkaline phosphatase.</li>
<li>Monitor carefully for and immediately report S&amp;S of GI bleeding and hypocalcemia.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn administration guidelines regarding upright position, empty stomach, and spacing relative to calcium supplements and
            antacids must be strictly followed.
         </li>
<li>Report any of the following to physician: eye irritation, significant GI upset, or flu-like symptoms.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>